Ceapro Inc. Report is updated and rated Speculative Buy at $0.54. This is a risky penny stock. In retrospect it is regrettable that I ever happened to look at it and add it to the site back in 2017. But it is profitable and I will continue to update it periodically. I have long said that it a lottery ticket type investment. Suitable for only a modest investment. It has several research irons in the fire which it seems to believe could pay off big. But one of those was a research trial of its Beta Glucan pills (for cholesterol reduction) which turned out to be a bust. The trial results released last month showed no statistically significant benefit. They did seem to allude that perhaps there was a benefit but it just was not statistically significant. I don’t like that they alluded to this without being clear. They even mentioned that there was some indication of weight loss on the pills, also not large enough to be statistically significant – in other words could be random. Mentioning this weak possible weight loss impact seemed to me to be a pathetic grasp at a straw. Other studies HAVE shown some benefit of Beta Glucan as a cholesterol reducer. They may be able to license out their pills in any case. They would be sold as non-prescription nutraceuticals and believers may buy. But that would seem to put them in the “snake oil” business which is disappointing.